Celltrion unveils KRW 1.2 trillion Songdo expansion, boosting DS production capacity by 180,000L to a total of 570,000L
Celltrion has unveiled an ambitious and far-reaching investment strategy aimed at significantly expanding its global manufacturing footprint, reinforcing its position in the increasingly competitive biologics market. The company announced plans to invest more than KRW 1 trillion in large-scale infrastructure development, with a particular focus on its Songdo headquarters in South Korea, as well as key international and domestic production sites. This initiative reflects Celltrion’s strategic intent to address surging global demand for biologic therapies while laying a robust foundation for long-term growth across biosimilars, innovative drugs, and contract manufacturing operations.
The multi-phase expansion program, scheduled to unfold between 2026 and 2030, represents one of the most substantial manufacturing investments in the company’s history. Rather than focusing solely on increasing production capacity, the initiative is designed to transform Celltrion’s manufacturing ecosystem into a highly integrated, technologically advanced network capable of supporting a diverse and expanding product portfolio. This includes next-generation biosimilars, novel biologic therapies currently in development, and third-party manufacturing services through its growing contract manufacturing organization (CMO) business.
Strategic Expansion at Songdo: Building Next-Generation Capacity
At the heart of this initiative lies a KRW 1.2265 trillion investment in the Songdo campus, located in Incheon, South Korea. This site serves as Celltrion’s global headquarters and primary production hub. The company plans to construct two new large-scale manufacturing facilities—Plants 4 and 5—which will collectively add 180,000 liters of drug substance (DS) production capacity.
These facilities are being designed with cutting-edge automation systems and smart factory technologies, reflecting the industry’s shift toward digitalized and highly efficient biomanufacturing processes. By integrating advanced process controls, data analytics, and flexible production systems, Celltrion aims to maximize operational efficiency while maintaining high quality standards. This technological upgrade will allow the company to handle a wide range of production scenarios, from small-batch, multi-product runs to large-scale commercial manufacturing.
The flexibility offered by these new plants is particularly important given the evolving nature of Celltrion’s pipeline. As the company continues to develop both biosimilars and innovative biologics, the ability to quickly adapt production lines to different products and scales will be critical. The new facilities are expected to support not only existing blockbuster products but also upcoming pipeline candidates, ensuring timely market entry and reliable supply.
Moreover, the expansion is strategically aligned with the growing demand for contract manufacturing services. As global pharmaceutical companies increasingly outsource production to specialized partners, Celltrion aims to position itself as a leading CMO provider by offering high-quality, scalable, and cost-effective manufacturing solutions.
Strengthening U.S. Manufacturing Capabilities
In parallel with its domestic expansion, Celltrion is also enhancing its manufacturing presence in the United States, a key market for biologics. The company has finalized plans to expand its facility in Branchburg, New Jersey, increasing its drug substance production capacity from 66,000 liters to 141,000 liters. This represents an additional 75,000 liters of capacity—an upgrade from the originally proposed 66,000 liters expansion.
The Branchburg facility plays a critical role in Celltrion’s global strategy, particularly as demand for locally manufactured biologics continues to rise in the United States. By strengthening its U.S.-based production capabilities, the company aims to ensure a stable and responsive supply chain for its products in one of the world’s largest pharmaceutical markets.
This expansion also serves as a strategic hedge against potential trade barriers, including tariffs and regulatory complexities associated with cross-border supply chains. By producing biologics locally, Celltrion can enhance its competitiveness, improve margins, and reduce logistical risks. Additionally, the facility will support the company’s CMO business, enabling it to serve U.S.-based clients more effectively.
Once the planned expansions in both South Korea and the United States are completed, Celltrion’s total global drug substance production capacity will increase dramatically—from 316,000 liters to approximately 571,000 liters. This milestone is expected to enable full internalization of DS manufacturing, allowing the company to produce all required drug substances in-house. Such vertical integration is anticipated to deliver significant cost savings and improve supply chain reliability.
Expanding Drug Product Manufacturing Capabilities
Beyond drug substance production, Celltrion is also making substantial investments in drug product (DP) manufacturing, which involves the final formulation and packaging of biologic therapies. Strengthening DP capabilities is a critical component of the company’s strategy to enhance overall manufacturing efficiency and reduce reliance on external partners.
At the Songdo campus, a new DP manufacturing plant is currently under construction and has already surpassed 70% completion. The facility is expected to be finalized within the year, with commercial operations slated to begin the following year. Once operational, the plant will function as a dedicated DP production facility, capable of producing up to 6.5 million liquid vials annually.
When combined with the existing DP production line at Plant 2—which has a capacity of 4 million vials per year—Celltrion will achieve a total annual DP output of approximately 10.5 million vials in Songdo alone. This significant increase in capacity will enable the company to meet growing global demand while maintaining high levels of quality and consistency.
In addition to the Songdo expansion, Celltrion has identified a new site for a DP manufacturing facility in the Yesan Industrial Complex in Chungcheongnam-do, South Korea. The company plans to initiate design work for this facility within the year, further extending its domestic production capabilities.
The Yesan facility, along with planned expansions in pre-filled syringe (PFS) manufacturing by Celltrion Pharm, is expected to play a key role in achieving the company’s goal of internalizing approximately 90% of its global DP supply volume. This level of internalization would significantly reduce dependence on external contract manufacturers, leading to substantial cost savings and improved control over production timelines.
A Dual-Track Global Manufacturing Strategy
The comprehensive expansion plan underscores Celltrion’s commitment to implementing a dual-track manufacturing strategy that leverages both domestic and international production capabilities. This approach is designed to maximize flexibility and responsiveness in a rapidly changing global market.
Domestic facilities in South Korea will focus on enhancing production internalization and cost efficiency, enabling the company to remain competitive in global tenders and expand its presence in markets outside the United States. Meanwhile, the U.S.-based manufacturing site will serve as a localized supply hub, ensuring timely delivery of products to American customers and mitigating potential trade-related risks.
This balanced strategy allows Celltrion to optimize its operations across different regions, taking advantage of local market conditions while maintaining a cohesive global supply chain. It also positions the company to respond more effectively to fluctuations in demand, regulatory changes, and economic uncertainties.
Commitment to Safety and Sustainable Growth
As it undertakes multiple large-scale construction projects, Celltrion has emphasized its commitment to safety and regulatory compliance. The company is conducting comprehensive reviews of safety management systems across all construction sites, ensuring that safety remains the top priority throughout the expansion process.
This focus on safety extends beyond construction to include operational practices within the new facilities. By adhering to stringent quality and safety standards, Celltrion aims to maintain its reputation as a reliable and responsible biopharmaceutical manufacturer.
Positioning for Future Growth
Looking ahead, Celltrion remains open to further expansion opportunities, depending on market conditions and the progress of its product pipeline. As the global biologics market continues to grow—driven by increasing demand for biosimilars and innovative therapies—the company is prepared to scale its manufacturing capabilities accordingly.
Company representatives have highlighted that this investment is not only about meeting current demand but also about preparing for the future. By building a comprehensive manufacturing infrastructure that supports both biosimilars and innovative drugs, as well as a growing CMO business, Celltrion aims to solidify its position as a top-tier global biopharmaceutical company.
In summary, Celltrion’s multi-billion-won expansion initiative represents a transformative step in its evolution. By significantly increasing production capacity, embracing advanced manufacturing technologies, and strengthening its global footprint, the company is well-positioned to capitalize on emerging opportunities in the biologics sector. Through this strategic investment, Celltrion is not only enhancing its operational capabilities but also reinforcing its long-term vision of delivering high-quality, accessible biologic therapies to patients worldwide.
Source Link:https://www.celltrion.com/
